Former investment banker tapped as new Shire chairwoman

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Former investment banker tapped as new Shire chairwoman

Shire ($SHPG) CEO Flemming Ornskov has tapped Susan Kilsby to be the company's chairwoman. She will replace Matthew Emmens, Shire's former CEO and chairman since 2008, who is retiring. Kilsby, a former investment banker, joined the Shire board as a nonexecutive director in September 2011. Story

Shire
Susan Kilsby will become the new chairwoman. 


Vivus
CFO Timothy Morris is stepping down.


Pharma

Vivus ($VVUS) CFO Timothy Morris is stepping down. The company's controller, Svai Sanford, will fill the position on an interim basis. Story

> NextPharma Technologies appointed Eric Bertrand as the head of its liquids arm in Limay, France; Ralf Blesel as the head of its penicillin branch in Berlin; and Nigel Cryer as vice president of quality and regulatory functions. Release

Alacrita named Pierre Dodion an associate partner. Release

Biotech

Dr. Justin Klamerus has been named chief quality officer and executive vice president of community-based programs for the Barbara Ann Karmanos Cancer Institute. Release

> Dr. Mahmoud Ghazzi joined Daiichi Sankyo as the company's global head of drug development. Release

Spark Therapeutics has named Dr. Rogerio Vivaldi, formerly the senior vice president and head of rare diseases at Genzyme, as its first independent board member. Release

Keryx Biopharmaceuticals ($KERX) has appointed Daniel Olmstead to the newly created position of vice president of payer access. Release

The Illinois Biotechnology Industry Organization has elected Andy Hull as chairman of the iBIO board of directors and Linda Friedman as chairperson of the iBIO Institute board of directors. Release

Ryan Daws was appointed chief financial officer of Concert Pharmaceuticals. Release

Curtis Carlson, CEO and president of SRI International, is retiring after 16 years in the position and 40 years of service with the organization. Release

PTC Therapeutics ($PTCT) has appointed Dr. Robert Spiegel chief medical officer and Murad Husain vice president of global regulatory affairs. Release

Imugene appointed Christoph Zielinski and Dr. Ursula Wiedermann to its scientific advisory board. Release

Emerson Ecologics brought Corey Schuler and Diana Noland onto its practitioner advisory council. Release

Autonomic Technologies appointed Dr. Shashidhar Kori as its chief medical officer. Release

Advanced Cell Technology's CEO Gary Rabin left his position abruptly, and CFO Edward Myles will act as interim until a replacement is found. Release

Former FDA commissioner Dr. Andrew von Eschenbach and former Deputy Assistant Secretary of Treasury Wesley Yin joined healthcare consulting company Precision Health Economics. Release

CRO

Icon ($ICLR) named Dariush Elahi as the company's head of metabolic research. Release

Asli Turkes and Susan Timoney joined INC Research's oncology team as vice president of clinical development and executive director of clinical development, respectively. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.